Cardiomyocytes derived from human induced pluripotent stem cells as models for normal and diseased cardiac electrophysiology and contractility

Progress in Biophysics and Molecular Biology

Volumn 110, Issue 2-3, 2012, Pages 166-177

  Blazeski, Adriana ^a   Zhu, Renjun ^a   Hunter, David W ^a   Weinberg, Seth H ^a   Zambidis, Elias T ^b   Tung, Leslie ^a  

^a Johns Hopkins University   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cardiac cell; Contraction; Electrophysiology; Embryoid body; Human induced pluripotent stem cell; Optical mapping

Indexed keywords

BIOLACTIN; LACTIC ACID;

ANIMAL; CYTOLOGY; ELECTROPHYSIOLOGY; HEART; HEART CONTRACTION; HEART DISEASE; HEART MUSCLE CELL; HUMAN; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PLURIPOTENT STEM CELL; REVIEW;

ANIMALS; ELECTROPHYSIOLOGICAL PROCESSES; HEART; HEART DISEASES; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LACTIC ACID; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC;

EID: 84868093154     PISSN: 00796107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbiomolbio.2012.07.013     Document Type: Review

References (113)

1. Anderson D., Self T., Mellor I.R., Goh G., Hill S.J., Denning C. Transgenic enrichment of cardiomyocytes from human embryonic stem cells. Mol. Ther. 2007, 15:2027-2036.
2. Blazeski A., Zhu R., Hunter D.W., Weinberg S.H., Boheler K.R., Zambidis E.T., Tung L. Electrophysiological and contractile function of cardiomyocytes derived from human embryonic stem cells. Prog. Biophys. Mol. Biol. 2012, 110(2-3):178-195.
3. Braam S.R., Tertoolen L., van de Stolpe A., Meyer T., Passier R., Mummery C.L. Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Res. 2010, 4:107-116.
4. Burridge P.W., Anderson D., Priddle H., Barbadillo Munoz M.D., Chamberlain S., Allegrucci C., Young L.E., Denning C. Improved human embryonic stem cell embryoid body homogeneity and cardiomyocyte differentiation from a novel V-96 plate aggregation system highlights interline variability. Stem Cells 2007, 25:929-938.
5. Burridge P.W., Keller G., Gold J.D., Wu J.C. Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell 2012, 10:16-28.
6. Burridge P.W., Thompson S., Millrod M.A., Weinberg S., Yuan X., Peters A., Mahairaki V., Koliatsos V.E., Tung L., Zambidis E.T. A universal system for highly efficient cardiac differentiation of human induced pluripotent stem cells that eliminates interline variability. PLoS One 2011, 6:e18293.
7. Carvajal-Vergara X., Sevilla A., D'Souza S.L., Ang Y.S., Schaniel C., Lee D.F., Yang L., Kaplan A.D., Adler E.D., Rozov R., Ge Y., Cohen N., Edelmann L.J., Chang B., Waghray A., Su J., Pardo S., Lichtenbelt K.D., Tartaglia M., Gelb B.D., Lemischka I.R. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 2010, 465:808-812.
8. Caspi O., Itzhaki I., Kehat I., Gepstein A., Arbel G., Huber I., Satin J., Gepstein L. In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes. Stem Cells Dev. 2009, 18:161-172.
9. Chaudhary K.W., Barrezueta N.X., Bauchmann M.B., Milici A.J., Beckius G., Stedman D.B., Hambor J.E., Blake W.L., McNeish J.D., Bahinski A., Cezar G.G. Embryonic stem cells in predictive cardiotoxicity: laser capture microscopy enables assay development. Toxicol. Sci. 2006, 90:149-158.
10. Cohen J.D., Babiarz J.E., Abrams R.M., Guo L., Kameoka S., Chiao E., Taunton J., Kolaja K.L. Use of human stem cell derived cardiomyocytes to examine sunitinib mediated cardiotoxicity and electrophysiological alterations. Toxicol. Appl. Pharmacol. 2011, 257:74-83.
11. Crotti L., Celano G., Dagradi F., Schwartz P.J. Congenital long QT syndrome. Orphanet J. Rare Dis. 2008, 3:18.
12. Dambrot C., Passier R., Atsma D., Mummery C.L. Cardiomyocyte differentiation of pluripotent stem cells and their use as cardiac disease models. Biochem. J. 2011, 434:25-35.
13. Davis R.P., van den Berg C.W., Casini S., Braam S.R., Mummery C.L. Pluripotent stem cell models of cardiac disease and their implication for drug discovery and development. Trends Mol. Med. 2011, 17:475-484.
14. di Barletta M.R., Viatchenko-Karpinski S., Nori A., Memmi M., Terentyev D., Turcato F., Valle G., Rizzi N., Napolitano C., Gyorke S., Volpe P., Priori S.G. Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia. Circulation 2006, 114:1012-1019.
15. Digilio M.C., Conti E., Sarkozy A., Mingarelli R., Dottorini T., Marino B., Pizzuti A., Dallapiccola B. Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. Am. J. Hum. Genet. 2002, 71:389-394.
16. Drouin E., Charpentier F., Gauthier C., Laurent K., Le Marec H. Electrophysiologic characteristics of cells spanning the left ventricular wall of human heart: evidence for presence of M cells. J. Am. Coll. Cardiol. 1995, 26:185-192.
17. Edouard T., Montagner A., Dance M., Conte F., Yart A., Parfait B., Tauber M., Salles J.P., Raynal P. How do Shp2 mutations that oppositely influence its biochemical activity result in syndromes with overlapping symptoms?. Cell Mol. Life Sci. 2007, 64:1585-1590.
18. Eisner D.A., Kashimura T., O'Neill S.C., Venetucci L.A., Trafford A.W. What role does modulation of the ryanodine receptor play in cardiac inotropy and arrhythmogenesis?. J. Mol. Cell Cardiol. 2009, 46:474-481.
19. Endoh M. Force-frequency relationship in intact mammalian ventricular myocardium: physiological and pathophysiological relevance. Eur. J. Pharmacol. 2004, 500:73-86.
20. Farokhpour M., Karbalaie K., Tanhaei S., Nematollahi M., Etebari M., Sadeghi H.M., Nasr-Esfahani M.H., Baharvand H. Embryonic stem cell-derived cardiomyocytes as a model system to study cardioprotective effects of dexamethasone in doxorubicin cardiotoxicity. Toxicol. In Vitro 2009, 23:1422-1428.
21. Fermini B., Fossa A.A. The impact of drug-induced QT interval prolongation on drug discovery and development. Nat. Rev. Drug Discov. 2003, 2:439-447.
22. Freund C., Mummery C.L. Prospects for pluripotent stem cell-derived cardiomyocytes in cardiac cell therapy and as disease models. J. Cell Biochem. 2009, 107:592-599.
23. 2+ exchanger is a determinant of excitation-contraction coupling in human embryonic stem cell-derived ventricular cardiomyocytes. Stem Cells Dev. 2010, 19:773-782.
24. Fu J.D., Rushing S.N., Lieu D.K., Chan C.W., Kong C.W., Geng L., Wilson K.D., Chiamvimonvat N., Boheler K.R., Wu J.C., Keller G., Hajjar R.J., Li R.A. Distinct roles of microRNA-1 and -499 in ventricular specification and functional maturation of human embryonic stem cell-derived cardiomyocytes. PLoS One 2011, 6:e27417.
25. Fujiwara M., Yan P., Otsuji T.G., Narazaki G., Uosaki H., Fukushima H., Kuwahara K., Harada M., Matsuda H., Matsuoka S., Okita K., Takahashi K., Nakagawa M., Ikeda T., Sakata R., Mummery C.L., Nakatsuji N., Yamanaka S., Nakao K., Yamashita J.K. Induction and enhancement of cardiac cell differentiation from mouse and human induced pluripotent stem cells with cyclosporin-A. PLoS One 2011, 6:e16734.
26. Gai H., Leung E.L., Costantino P.D., Aguila J.R., Nguyen D.M., Fink L.M., Ward D.C., Ma Y. Generation and characterization of functional cardiomyocytes using induced pluripotent stem cells derived from human fibroblasts. Cell Biol. Int. 2009, 33:1184-1193.
27. Germanguz I., Sedan O., Zeevi-Levin N., Shtrichman R., Barak E., Ziskind A., Eliyahu S., Meiry G., Amit M., Itskovitz-Eldor J., Binah O. Molecular characterization and functional properties of cardiomyocytes derived from human inducible pluripotent stem cells. J. Cell Mol. Med. 2011, 15:38-51.
28. Gherghiceanu M., Barad L., Novak A., Reiter I., Itskovitz-Eldor J., Binah O., Popescu L.M. Cardiomyocytes derived from human embryonic and induced pluripotent stem cells: comparative ultrastructure. J. Cell Mol. Med. 2011, 15:2539-2551.
29. Gorlin R.J., Anderson R.C., Moller J.H. The leopard (multiple lentigines) syndrome revisited. Laryngoscope 1971, 81:1674-1681.
30. Guo L., Abrams R.M., Babiarz J.E., Cohen J.D., Kameoka S., Sanders M.J., Chiao E., Kolaja K.L. Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol. Sci. 2011, 123:281-289.
31. Guo L., Qian J.Y., Abrams R., Tang H.M., Weiser T., Sanders M.J., Kolaja K.L. The electrophysiological effects of cardiac glycosides in human iPSC-derived cardiomyocytes and in guinea pig isolated hearts. Cell Physiol. Biochem. 2011, 27:453-462.
32. Gupta M.K., Illich D.J., Gaarz A., Matzkies M., Nguemo F., Pfannkuche K., Liang H., Classen S., Reppel M., Schultze J.L., Hescheler J., Sarif{hook}á T. Global transcriptional profiles of beating clusters derived from human induced pluripotent stem cells and embryonic stem cells are highly similar. BMC Dev. Biol. 2010, 10:98.
33. Haase A., Olmer R., Schwanke K., Wunderlich S., Merkert S., Hess C., Zweigerdt R., Gruh I., Meyer J., Wagner S., Maier L.S., Han D.W., Glage S., Miller K., Fischer P., Scholer H.R., Martin U. Generation of induced pluripotent stem cells from human cord blood. Cell Stem Cell 2009, 5:434-441.
34. Habib M., Caspi O., Gepstein L. Human embryonic stem cells for cardiomyogenesis. J. Mol. Cell Cardiol. 2008, 45:462-474.
35. Halbach M., Egert U., Hescheler J., Banach K. Estimation of action potential changes from field potential recordings in multicellular mouse cardiac myocyte cultures. Cell Physiol. Biochem.: Int. J. Exp. Cell. Physiol. Biochem. Pharmacol. 2003, 13:271-284.
36. Hamlin R.L. Animal models of ventricular arrhythmias. Pharmacol. Ther. 2007, 113:276-295.
37. He J.Q., Ma Y., Lee Y., Thomson J.A., Kamp T.J. Human embryonic stem cells develop into multiple types of cardiac myocytes: action potential characterization. Circ. Res. 2003, 93:32-39.
38. Itzhaki I., Maizels L., Huber I., Zwi-Dantsis L., Caspi O., Winterstern A., Feldman O., Gepstein A., Arbel G., Hammerman H., Boulos M., Gepstein L. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011, 471:225-229.
39. Itzhaki I., Rapoport S., Huber I., Mizrahi I., Zwi-Dantsis L., Arbel G., Schiller J., Gepstein L. Calcium handling in human induced pluripotent stem cell derived cardiomyocytes. PLoS One 2011, 6:e18037.
40. Jia F., Wilson K.D., Sun N., Gupta D.M., Huang M., Li Z., Panetta N.J., Chen Z.Y., Robbins R.C., Kay M.A., Longaker M.T., Wu J.C. A nonviral minicircle vector for deriving human iPS cells. Nat. Methods 2010, 7:197-199.
41. Josowitz R., Carvajal-Vergara X., Lemischka I.R., Gelb B.D. Induced pluripotent stem cell-derived cardiomyocytes as models for genetic cardiovascular disorders. Curr. Opin. Cardiol. 2011, 26:223-229.
42. Jung C.B., Moretti A., Mederos Y.S.M., Iop L., Storch U., Bellin M., Dorn T., Ruppenthal S., Pfeiffer S., Goedel A., Dirschinger R.J., Seyfarth M., Lam J.T., Sinnecker D., Gudermann T., Lipp P., Laugwitz K.L. Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. EMBO. Mol. Med. 2012, 4:180-191.
43. ++ channel pharmacology between native and stem cell-derived cardiomyocytes. J. Pharmacol. Exp. Ther. 2012.
44. Kapucu F.E., Pekkanen-Mattila M., Kujala V., Viik J., Aalto-Setela K., Kerkela E., Tanskanen J.M.A., Hyttinen J. Beating rate variability studies with human embryonic stem cell derived cardiomyocytes. IFMBE Proc. 2008, 22:8-11.
45. Kim C., Majdi M., Xia P., Wei K.A., Talantova M., Spiering S., Nelson B., Mercola M., Chen H.S. Non-cardiomyocytes influence the electrophysiological maturation of human embryonic stem cell-derived cardiomyocytes during differentiation. Stem Cells Dev. 2010, 19:783-795.
46. Kim K., Doi A., Wen B., Ng K., Zhao R., Cahan P., Kim J., Aryee M.J., Ji H., Ehrlich L.I., Yabuuchi A., Takeuchi A., Cunniff K.C., Hongguang H., McKinney-Freeman S., Naveiras O., Yoon T.J., Irizarry R.A., Jung N., Seita J., Hanna J., Murakami P., Jaenisch R., Weissleder R., Orkin S.H., Weissman I.L., Feinberg A.P., Daley G.Q. Epigenetic memory in induced pluripotent stem cells. Nature 2010, 467:285-290.
47. Kim K., Zhao R., Doi A., Ng K., Unternaehrer J., Cahan P., Huo H., Loh Y.H., Aryee M.J., Lensch M.W., Li H., Collins J.J., Feinberg A.P., Daley G.Q. Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells. Nat. Biotechnol. 2011, 29:1117-1119.
48. Kim K.Y., Hysolli E., Park I.H. Reprogramming human somatic cells into induced pluripotent stem cells (iPSCs) using retroviral vector with GFP. J. Vis. Exp. 2012.
49. Kim Y.Y., Ku S.Y., Liu H.C., Cho H.J., Oh S.K., Moon S.Y., Choi Y.M. Cryopreservation of human embryonic stem cells derived-cardiomyocytes induced by BMP2 in serum-free condition. Reprod. Sci. 2011, 18:252-260.
50. Kong C.W., Akar F.G., Li R.A. Translational potential of human embryonic and induced pluripotent stem cells for myocardial repair: insights from experimental models. Thromb. Haemost. 2010, 104:30-38.
51. Laflamme M.A., Chen K.Y., Naumova A.V., Muskheli V., Fugate J.A., Dupras S.K., Reinecke H., Xu C., Hassanipour M., Police S., O'Sullivan C., Collins L., Chen Y., Minami E., Gill E.A., Ueno S., Yuan C., Gold J., Murry C.E. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat. Biotechnol. 2007, 25:1015-1024.
52. Lahti A.L., Kujala V.J., Chapman H., Koivisto A.P., Pekkanen-Mattila M., Kerkela E., Hyttinen J., Kontula K., Swan H., Conklin B.R., Yamanaka S., Silvennoinen O., Aalto-Setala K. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis. Model. Mech. 2011.
53. Lee Y.K., Ng K.M., Lai W.H., Chan Y.C., Lau Y.M., Lian Q., Tse H.F., Siu C.W. Calcium homeostasis in human induced pluripotent stem cell-derived cardiomyocytes. Stem Cell Rev. 2011, 7:976-986.
54. + current in human ventricular myocytes. Circ. Res. 1996, 78:689-696.
55. Liang H., Matzkies M., Schunkert H., Tang M., Bonnemeier H., Hescheler J., Reppel M. Human and murine embryonic stem cell-derived cardiomyocytes serve together as a valuable model for drug safety screening. Cell Physiol. Biochem. 2010, 25:459-466.
56. Limongelli G., Pacileo G., Marino B., Digilio M.C., Sarkozy A., Elliott P., Versacci P., Calabro P., De Zorzi A., Di Salvo G., Syrris P., Patton M., McKenna W.J., Dallapiccola B., Calabro R. Prevalence and clinical significance of cardiovascular abnormalities in patients with the LEOPARD syndrome. Am. J. Cardiol. 2007, 100:736-741.
57. Ma J., Guo L., Fiene S.J., Anson B.D., Thomson J.A., Kamp T.J., Kolaja K.L., Swanson B.J., January C.T. High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. Am. J. Physiol. Heart Circ. Physiol. 2011, 301:H2006-H2017.
58. Magyar J., Iost N., Kortvely A., Banyasz T., Virag L., Szigligeti P., Varro A., Opincariu M., Szecsi J., Papp J.G., Nanasi P.P. Effects of endothelin-1 on calcium and potassium currents in undiseased human ventricular myocytes. Pflugers Arch. 2000, 441:144-149.
59. Maltsev V.A., Lakatta E.G. Normal heart rhythm is initiated and regulated by an intracellular calcium clock within pacemaker cells. Heart Lung Circ. 2007, 16:335-348.
60. Mandel Y., Weissman A., Schick R., Barad L., Novak A., Meiry G., Goldberg S., Lorber A., Rosen M.R., Itskovitz-Eldor J., Binah O. Human embryonic and induced pluripotent stem cells-derived cardiomyocytes exhibit beat rate variability and Power-Law behavior. Circulation 2012.
61. Marban E. Cardiac channelopathies. Nature 2002, 415:213-218.
62. Martinez-Fernandez A., Nelson T.J., Yamada S., Reyes S., Alekseev A.E., Perez-Terzic C., Ikeda Y., Terzic A. iPS programmed without c-MYC yield proficient cardiogenesis for functional heart chimerism. Circ. Res. 2009, 105:648-656.
63. Matsa E., Rajamohan D., Dick E., Young L., Mellor I., Staniforth A., Denning C. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur. Heart J. 2011, 32:952-962.
64. Maury Y., Gauthier M., Peschanski M., Martinat C. Human pluripotent stem cells for disease modelling and drug screening. Bioessays 2012, 34:61-71.
65. McCauley M.D., Wehrens X.H. Animal models of arrhythmogenic cardiomyopathy. Dis. Model. Mech. 2009, 2:563-570.
66. McNeish J. Embryonic stem cells in drug discovery. Nat. Rev. Drug Discov. 2004, 3:70-80.
67. Mehta A., Chung Y.Y., Ng A., Iskandar F., Atan S., Wei H., Dusting G., Sun W., Wong P., Shim W. Pharmacological response of human cardiomyocytes derived from virus-free induced pluripotent stem cells. Cardiovasc. Res. 2011, 91:577-586.
68. Milan D.J., MacRae C.A. Animal models for arrhythmias. Cardiovasc. Res. 2005, 67:426-437.
69. Miura K., Okada Y., Aoi T., Okada A., Takahashi K., Okita K., Nakagawa M., Koyanagi M., Tanabe K., Ohnuki M., Ogawa D., Ikeda E., Okano H., Yamanaka S. Variation in the safety of induced pluripotent stem cell lines. Nat. Biotechnol. 2009, 27:743-745.
70. Moretti A., Bellin M., Welling A., Jung C.B., Lam J.T., Bott-Flágel L., Dorn T., Goedel A., Höhnke C., Hofmann F., Seyfarth M., Sinnecker D., Schömig A., Laugwitz K.L. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N. Engl. J. Med. 2010, 363:1397-1409.
71. Morris C.E., Juranka P.F., Joós B. Perturbed voltage-gated channel activity in perturbed bilayers: implications for ectopic arrhythmias arising from damaged membrane. Prog. Biophys. Mol. Biol. 2012, 110(2-3):245-256.
72. Mummery C., Ward-van Oostwaard D., Doevendans P., Spijker R., van den Brink S., Hassink R., van der Heyden M., Opthof T., Pera M., de la Riviere A.B., Passier R., Tertoolen L. Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation 2003, 107:2733-2740.
73. Nakagawa M., Koyanagi M., Tanabe K., Takahashi K., Ichisaka T., Aoi T., Okita K., Mochiduki Y., Takizawa N., Yamanaka S. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat. Biotechnol. 2008, 26:101-106.
74. Narsinh K.H., Sun N., Sanchez-Freire V., Lee A.S., Almeida P., Hu S., Jan T., Wilson K.D., Leong D., Rosenberg J., Yao M., Robbins R.C., Wu J.C. Single cell transcriptional profiling reveals heterogeneity of human induced pluripotent stem cells. J. Clin. Invest. 2011, 121:1217-1221.
75. Novak A., Barad L., Zeevi-Levin N., Shick R., Shtrichman R., Lorber A., Itskovitz-Eldor J., Binah O. Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to beta-adrenergic stimulation. J. Cell Mol. Med. 2012, 16:468-482.
76. Novak A., Shtrichman R., Germanguz I., Segev H., Zeevi-Levin N., Fishman B., Mandel Y.E., Barad L., Domev H., Kotton D., Mostoslavsky G., Binah O., Itskovitz-Eldor J. Enhanced reprogramming and cardiac differentiation of human keratinocytes derived from plucked hair follicles, using a single excisable lentivirus. Cell Reprogram 2010, 12:665-678.
77. Nsair A., MacLellan W.R. Induced pluripotent stem cells for regenerative cardiovascular therapies and biomedical discovery. Adv. Drug Deliv. Rev. 2011, 63:324-330.
78. O'Hara T., Virag L., Varro A., Rudy Y. Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation. PLoS Comput. Biol. 2011, 7:e1002061.
79. Okita K., Nakagawa M., Hyenjong H., Ichisaka T., Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008, 322:949-953.
80. Osafune K., Caron L., Borowiak M., Martinez R.J., Fitz-Gerald C.S., Sato Y., Cowan C.A., Chien K.R., Melton D.A. Marked differences in differentiation propensity among human embryonic stem cell lines. Nat. Biotechnol. 2008, 26:313-315.
81. Pal R., Totey S., Mamidi M.K., Bhat V.S. Propensity of human embryonic stem cell lines during early stage of lineage specification controls their terminal differentiation into mature cell types. Exp. Biol. Med. (Maywood) 2009, 234:1230-1243.
82. Pekkanen-Mattila M., Kerkela E., Tanskanen J.M., Pietila M., Pelto-Huikko M., Hyttinen J., Skottman H., Suuronen R., Aalto-Setala K. Substantial variation in the cardiac differentiation of human embryonic stem cell lines derived and propagated under the same conditions-a comparison of multiple cell lines. Ann. Med. 2009, 41:360-370.
83. Pelzmann B., Schaffer P., Bernhart E., Lang P., Machler H., Rigler B., Koidl B. L-type calcium current in human ventricular myocytes at a physiological temperature from children with tetralogy of Fallot. Cardiovasc. Res. 1998, 38:424-432.
84. Polo J.M., Liu S., Figueroa M.E., Kulalert W., Eminli S., Tan K.Y., Apostolou E., Stadtfeld M., Li Y., Shioda T., Natesan S., Wagers A.J., Melnick A., Evans T., Hochedlinger K. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat. Biotechnol. 2010, 28:848-855.
85. Poon E., Kong C.W., Li R.A. Human pluripotent stem cell-based approaches for myocardial repair: from the electrophysiological perspective. Mol. Pharm. 2011, 8:1495-1504.
86. Reinecke H., Zhang M., Bartosek T., Murry C.E. Survival, integration, and differentiation of cardiomyocyte grafts: a study in normal and injured rat hearts. Circulation 1999, 100:193-202.
87. Ren Y., Lee M.Y., Schliffke S., Paavola J., Amos P.J., Ge X., Ye M., Zhu S., Senyei G., Lum L., Ehrlich B.E., Qyang Y. Small molecule Wnt inhibitors enhance the efficiency of BMP-4-directed cardiac differentiation of human pluripotent stem cells. J. Mol. Cell Cardiol. 2011, 51:280-287.
88. Reppel M., Boettinger C., Hescheler J. Beta-adrenergic and muscarinic modulation of human embryonic stem cell-derived cardiomyocytes. Cell Physiol. Biochem. 2004, 14:187-196.
89. Sarkozy A., Digilio M.C., Dallapiccola B. Leopard syndrome. Orphanet J. Rare Dis. 2008, 3:13.
90. Sartiani L., Bettiol E., Stillitano F., Mugelli A., Cerbai E., Jaconi M.E. Developmental changes in cardiomyocytes differentiated from human embryonic stem cells: a molecular and electrophysiological approach. Stem Cells 2007, 25:1136-1144.
91. Satin J., Kehat I., Caspi O., Huber I., Arbel G., Itzhaki I., Magyar J., Schroder E.A., Perlman I., Gepstein L. Mechanism of spontaneous excitability in human embryonic stem cell derived cardiomyocytes. J. Physiol. 2004, 559:479-496.
92. Splawski I., Timothy K.W., Decher N., Kumar P., Sachse F.B., Beggs A.H., Sanguinetti M.C., Keating M.T. Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc. Natl. Acad. Sci. USA 2005, 102:8089-8096. Discussion 8086-8.
93. Splawski I., Timothy K.W., Sharpe L.M., Decher N., Kumar P., Bloise R., Napolitano C., Schwartz P.J., Joseph R.M., Condouris K., Tager-Flusberg H., Priori S.G., Sanguinetti M.C., Keating M.T. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 2004, 119:19-31.
94. Stadtfeld M., Nagaya M., Utikal J., Weir G., Hochedlinger K. Induced pluripotent stem cells generated without viral integration. Science 2008, 322:945-949.
95. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
96. Tanaka T., Tohyama S., Murata M., Nomura F., Kaneko T., Chen H., Hattori F., Egashira T., Seki T., Ohno Y., Koshimizu U., Yuasa S., Ogawa S., Yamanaka S., Yasuda K., Fukuda K. In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes. Biochem. Biophys. Res. Commun. 2009, 385:497-502.
97. Tulloch N.L., Muskheli V., Razumova M.V., Korte F.S., Regnier M., Hauch K.D., Pabon L., Reinecke H., Murry C.E. Growth of engineered human myocardium with mechanical loading and vascular coculture. Circ. Res. 2011, 109:47-59.
98. Verkerk A.O., Wilders R., van Borren M.M., Peters R.J., Broekhuis E., Lam K., Coronel R., de Bakker J.M., Tan H.L. Pacemaker current (I(f)) in the human sinoatrial node. Eur. Heart J. 2007, 28:2472-2478.
99. Wang K., Terrenoire C., Sampson K., Iyer V., Osteen J.D., Lu J., Keller G.N.D., Kass R.S. Biophysical properties of slow potassium channels in human embryonic stem cell derived cardiomyocytes implicate subunit stoichiometry. J. Physiol. 2011, 589(24):6093-6104.
100. Wang Z., Yue L., White M., Pelletier G., Nattel S. Differential distribution of inward rectifier potassium channel transcripts in human atrium versus ventricle. Circulation 1998, 98:2422-2428.
101. Warren L., Manos P.D., Ahfeldt T., Loh Y.H., Li H., Lau F., Ebina W., Mandal P.K., Smith Z.D., Meissner A., Daley G.Q., Brack A.S., Collins J.J., Cowan C., Schlaeger T.M., Rossi D.J. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010, 7:618-630.
102. Weinberg S., Lipke E.A., Tung L. In vitro electrophysiological mapping of stem cells. Methods Mol. Biol. 2010, 660:215-237.
103. Wettwer E., Amos G.J., Posival H., Ravens U. Transient outward current in human ventricular myocytes of subepicardial and subendocardial origin. Circ. Res. 1994, 75:473-482.
104. Xu C., He J.Q., Kamp T.J., Police S., Hao X., O'Sullivan C., Carpenter M.K., Lebkowski J., Gold J.D. Human embryonic stem cell-derived cardiomyocytes can be maintained in defined medium without serum. Stem Cells Dev. 2006, 15:931-941.
105. Xu C., Police S., Rao N., Carpenter M.K. Characterization and enrichment of cardiomyocytes derived from human embryonic stem cells. Circ. Res. 2002, 91:501-508.
106. Xu X.Q., Soo S.Y., Sun W., Zweigerdt R. Global expression profile of highly enriched cardiomyocytes derived from human embryonic stem cells. Stem Cells 2009, 27:2163-2174.
107. Yazawa M., Hsueh B., Jia X., Pasca A.M., Bernstein J.A., Hallmayer J., Dolmetsch R.E. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 2011, 471:230-234.
108. Yokoo N., Baba S., Kaichi S., Niwa A., Mima T., Doi H., Yamanaka S., Nakahata T., Heike T. The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells. Biochem. Biophys. Res. Commun. 2009, 387:482-488.
109. Yu J., Hu K., Smuga-Otto K., Tian S., Stewart R., Slukvin, Thomson J.A. Human induced pluripotent stem cells free of vector and transgene sequences. Science 2009, 324:797-801.
110. Zeevi-Levin N., Itskovitz-Eldor J., Binah O. Cardiomyocytes derived from human pluripotent stem cells for drug screening. Pharmacol. Ther. 2012.
111. Zhang J., Wilson G.F., Soerens A.G., Koonce C.H., Yu J., Palecek S.P., Thomson J.A., Kamp T.J. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ. Res. 2009, 104:e30-41.
112. Zhou H., Wu S., Joo J.Y., Zhu S., Han D.W., Lin T., Trauger S., Bien G., Yao S., Zhu Y., Siuzdak G., Scholer H.R., Duan L., Ding S. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009, 4:381-384.
113. Zwi L., Caspi O., Arbel G., Huber I., Gepstein A., Park I.H., Gepstein L. Cardiomyocyte differentiation of human induced pluripotent stem cells. Circulation 2009, 120:1513-1523.